New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.
Axoltis ALS drug misses Phase 2 endpoint
Latest NewsFrench biotech Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the company enough encouragement to plan further development.
Cellectis scraps CAR-T pipeline in gene editing pivot
Latest NewsFrench biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease.
Genfit plans Phase 2 liver failure trial after acquiring immunomodulator from Inotrem
Latest NewsFrench biotech Genfit acquired nangibotide from Inotrem in the summer and plans to start a Phase 2a trial in acute-on-chronic liver failure (ACLF) in the fourth quarter.
GSK and Roche Chinese ADC bets deliver positive phase 3 data in SCLC
Latest NewsTwo B7-H3-targeted antibody-drug conjugates licensed from Chinese biotechs have now delivered positive phase 3 survival data in relapsed small-cell lung cancer, strengthening the oncology bets GSK and Roche made in China.
BioNTech adds clinical weight to its oncology pivot at WCLC 2026
Background, Latest NewsNew data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.
Allogenetics adds €3.8M for rejection-resistant donor lungs
Latest NewsHanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial planned for late 2027 or early 2028.
Simris steps on Heidelberg Pharma’s toes with amanitin pivot
Latest NewsSimris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less than two months after hiring the executive who helped build Heidelberg Pharma’s own amanitin platform.
EIB backs Ethris with €30 million for broad-spectrum antiviral mRNA
Latest NewsThe European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its mRNA-based antiviral candidate ETH47. The Munich-based RNA specialist has been working on the approach for several years. The EIB financing also highlights a persistent challenge in pandemic preparedness: broad-spectrum antivirals may have substantial societal value, but their commercial market is difficult to predict.
Northway opens €61M Vilnius plant built for personalized medicine
Latest NewsCDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being qualified for GMP manufacturing, and the company says it expects a manufacturing authorization from Lithuania’s State Medicines Control Agency within six months.
Connecta raises €3.1M for Fragile X syndrome Phase 2
Latest NewsThe Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027.